Cart
sales@molnova.com
EGFR-IN-76
CAS No. 2607829-38-7
EGFR-IN-76( —— )
Catalog No. M36624 CAS No. 2607829-38-7
EGFR-IN-76 is a potent EGFR inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 192 | In Stock |
|
| 5MG | 297 | In Stock |
|
| 10MG | 471 | In Stock |
|
| 25MG | 877 | In Stock |
|
| 50MG | 1408 | In Stock |
|
| 100MG | 1872 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEGFR-IN-76
-
NoteResearch use only, not for human use.
-
Brief DescriptionEGFR-IN-76 is a potent EGFR inhibitor.
-
DescriptionEGFR-IN-76 (compound 37A) is a potent inhibitor of EGFR. EGFR-IN-76 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2607829-38-7
-
Formula Weight561.05
-
Molecular FormulaC30H30ClFN6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (178.24 mM; Ultrasonic )
-
SMILESC(#CC=1C(NC(/C=C/CN2CCOCC2)=O)=CC3=C(C1)N=CN=C3NC4=C(F)C(Cl)=CC=C4)[C@]56[C@](C5)(CN(C)C6)[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lucas MC, et al. Preparation of alkynyl quinazoline compounds as anticancer agents. World Intellectual Property Organization, WO2021030711 A1. 2021-02-18.
molnova catalog
related products
-
Epertinib hydrochlor...
Epertinib hydrochloride shows potent antitumor activity.?
-
XL-647
XL-647 (Tesevatinib, EXEL-7647, KD-019) is a novel spectrum-selective kinase inhibitor that potently inhibits the EGFR, ErbB2, KDR and EphB4 with IC50 of 0.3, 16, 1.5 and 1.4 nM, respectively.
-
HKI-357
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s: 34 nM and 33 nM). HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.
